Coffee Could Protect Against Non-Alcoholic Fatty Liver Disease

April 27, 2016 Consuming coffee, even decaf, could protect against non-alcoholic fatty liver disease (NAFLD), according to a mouse study. Italian researchers studied three groups of mice over a 12-week period: One group received a standard diet, the second a high-fat diet and the third a high-fat diet along with…

Read More

Ending Hepatitis B and C Is a Monstrous Twin Challenge

April 27, 2016 Numerous obstacles stand in the way of ending the hepatitis B and C virus (HBV/HCV) epidemics in the United States. A new report from the National Academies of Sciences, Engineering and Medicine examines the challenges facing efforts to combat each disease and suggests that reducing both new…

Read More

Hepatitis B Prevalence High Among Syrian Refugees in Europe

April 22, 2016 As Germany continues to deal with an unprecedented influx of refugees and asylum seekers from war-torn countries like Syria, Afghanistan and Iraq, as well as from countries that make up the Horn of Africa, public health officials have begun looking for high rates of hepatitis B virus…

Read More

People Beat Hepatitis C Just As Well When Treated by Nonspecialists

April 22, 2016 People who receive hepatitis C virus (HCV) treatment from community-based treatment providers are cured at the same rate as those who see specialists, aidsmap reports. Researchers conducted a multicenter, open-label Phase IV clinical trial of 304 people treated with Harvoni (ledipasvir/sofosbuvir) at U.S. community health centers. Findings…

Read More

New Algorithm Predicts Who Will Benefit From End-Stage Liver Disease Treatment

April 19, 2016 Researchers have developed a new, highly accurate algorithm to predict who will benefit from intensive care unit treatment of end-stage liver disease. The investigators collected data on 354 people hospitalized with cirrhosis in centers in Belgium, Austria and Denmark. Findings were presented at the 51st International Liver…

Read More

New Tenofovir Is As Good As, Safer Than Old Version for Hepatitis B

April 19, 2016 Gilead Sciences’ updated version of Viread (tenofovir disoproxil fumarate, or TDF), tenofovir alafenamide (TAF), combats hepatitis B virus (HBV) comparably to and is safer than the older drug. Researchers conducted two randomized, double-blind, 96-week Phase III trials, called Studies 108 and 110, which included 1,298 treatment-naive and…

Read More

New Documentary Examines Hepatitis B Among Asian Americans

April 19, 2016 A new documentary aims to break the silence about hepatitis B virus (HBV) in Asian-American communities, the San Jose Mercury News reports. Be About It tells the stories of two local fathers living with HBV, and is making the rounds on the U.S. film festival circuit. Worldwide,…

Read More